top of page

Antibody Discovery

Prellis challenges LNOs™ with a variety of human target antigens, breaking tolerance and producing fully human antibody libraries with high affinity IgG with excellent diversity of sequence and epitope recognition.

Once challenged with the antigen of interest, our B cells produce high percentages of IgG antibodies. Human tolerance breaking is robust, and our antibody libraries have high levels of somatic hypermutation, diverse sequences, and demonstrate epitope binding diversity.


The EXIS™ platform can be leveraged to evaluate the human immunogenicity of potential therapeutic development candidates. LNOs™ challenged with therapeutics respond temporally in quantitatively measurable ways including cytokine responses and development of anti-drug antibodies.

Prellis Next-Generation I-O Therapeutics

Next Generation I-O Therapeutics

The tumor co-culture system enabling the interaction between our LNOs and biomimetic complex tumor models allows us to discover next generation immuno-oncology therapeutics.

Prellis Tumor Immune System

Tumor Immune System

Prellis technology can support large, complex tumor models mimicking tumor microenvironments, enabling interrogation of interactive biological systems for uniquely relevant prioritization of immuno-oncology therapeutics. Tumor cells grown in 3D more closely mimic tumors found in vivo. Prellis tumor models are 2 millimeters in diameter and can be used in longitudinal studies and transplantation.

Prellis Vaccine R&D

Vaccine R&D

Prellis allows direct access to understanding the immune response to vaccines for characterization and further development.

Externalized Immune System: EXIS™ Platform

EXIS Applications

EXIS™ Human Immune Response

Prellis utilizes its proprietary holographic printing technology to engineer 3D printed lymph node organoids (LNOs™) that recreates the human immunobiology in vitro allowing direct access to a fully functional human immune system. EXIS™ is a powerful and scalable platform with applications in antibody discovery (human and llama), immunogenicity evaluation, and in vitro tumor immune systems.

bottom of page